Latest Premedication Stories

SAN DIEGO, Oct. 26, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it met with the U.S. Food and Drug Administration (FDA) to discuss a single clinical study to support approval of ANX-514 (docetaxel for injectable emulsion), a detergent-free reformulation of Taxotere (docetaxel). ADVENTRX proposed a non-inferiority study (Study 514-02) with a primary objective of comparing fluid retention following treatment with ANX-514, administered without...

Out of every 1000 patients, two at most wake up during their operation. Unintended awareness in the patient is thus classified as an occasional complication of anesthesia"”but being aware of things happening during the operation, and being able to recall them later, can leave a patient with long-term psychological trauma.How to avoid such awareness events, and what treatment is available for a patient who does experience awareness, is the subject of a report by Petra Bischoff of the Ruhr...

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.A new study from the Research on Adverse Drug Events and Reports (RADAR) pharmacovigilance program at Northwestern University Feinberg School of Medicine identified 287 unique cases of hypersensitivity reactions submitted to the FDA's Adverse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received...